• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pyxis Oncology closes $152M Series B

March 30, 2021 By Sean Whooley

Pyxis LogoBiologics developer Pyxis Oncology announced today that it closed a Series B financing round worth $152 million.

Cambridge, Mass.-based Pyxis had its financing round co-led by Arix Bioscience and RTW Investments. Existing investors including Leaps by Bayer, Longwood Fund, Agent Capital and Ipsen also contributed to the $152 million, which brings Pyxis’ total funding to date to $174 million, according to a news release.

New investors, including Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, funds managed by Tekla Capital Management, Acuta Capital Partners, Ridgeback Capital Investments, Surveyor Capital, Laurion Capital Management, Logos Capital and LifeSci Venture Partners also participated in the financing round.

Pyxis plans to use the proceeds to advance its portfolio of antibody-drug conjugates (ADCs) that deliver highly potent targeted treatments directly to cancer cells. The company’s PYX-201 and PYX-203 therapeutics are both in-licensed from Pfizer, while PYX-202 is in-licensed by LegoChem Biosciences.

In conjunction with the funding, Arix Bioscience managing director Christian Schetter, RTW Investments head of strategic investments Dr. Gotham Makker and Pfizer Ventures partner Chris O’Donnell will join Pyxis’ board of directors.

“We are grateful for the support of these highly sophisticated investors as we strive to improve the lives of patients with difficult-to-treat cancers by progressing a diverse portfolio of potentially groundbreaking ADCs and immunotherapies,” Pyxis CEO Dr. Lara Sullivan said in the release. “This financing strengthens our ability to build a differentiated portfolio of biologics and allows us to accelerate our efforts to advance multiple promising programs into Phase 1 clinical trials.”

Filed Under: Business/Financial News, Featured, Funding Roundup, Oncology, Pharmaceuticals Tagged With: Pyxis Oncology

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS